VACCINE-PREVENTABLE VIRAL INFECTION / CARE & TRANSMISSION
Hepatitis B virus (HBV)
Hepatitis B can pass through sex or blood, and in some people it becomes a long-term liver infection. Vaccination prevents it well. Knowing whether someone is susceptible, immune or currently infected is more useful than a general percentage. [42][43][71]
Transmission risk
Risk by type of contact
Bottom line. HBV can be sexually transmitted, but vaccination is the best-quantified preventive measure here. Ordinary kissing is not an established route, and neither needle-exposure rates nor vaccine efficacy should be presented as condom effectiveness.
General
Oral
Vaginal
Anal
Kissing
What changes the risk (3)
- Vaccination. HIGH across vaccine evidence: completed vaccination is 80-100% effective against HBV infection or clinical hepatitis in cited evidence, not a sexual-route per-act estimate. Vaccine response and the endpoint are distinct. Sources 2
- Postexposure prevention. LOW for a sexual-act-specific percentage: vaccination and sometimes hepatitis B immune globulin are used according to prior immunity/source status; the effective intervention interval is unlikely to exceed 14 days after sexual exposure. Sources 4
- Source viral replication and blood. LOW for numerical sexual multipliers: current viremia, blood exposure, mucosal injury and recipient immunity matter. No validated menstruation/ejaculation factor; HBV antiviral suppression must not be labeled HIV-style U=U. Sources 2
Condoms and dental dams
Recommended to reduce sexual body-fluid exposure; no defensible HBV-specific perfect-use, consistent-use or dental-dam efficacy percentage was identified. Evidence: Low Sources 1, 2
* How to read these figures. Each is a published estimate under the conditions shown beside it, usually an untreated partner and a single act or partnership. It is not a prediction of your personal risk.
- Evidence: High
- Several prospective studies or a systematic review broadly agree.
- Evidence: Medium
- One or two studies, wide uncertainty, or a model.
- Evidence: Low
- Guideline judgment, case reports, or extrapolation.
Where no risk level is shown, the evidence cannot rank it. That is not the same as low.
Evidence reviewed through 2026-10-27. For reference only; not medical advice.
When to test after a possible exposure
HBV markers appear at different times. HBsAg can first be detectable about 1-2 weeks to 11-12 weeks after exposure; an early negative does not settle recent exposure.
When to be seen sooner. After a significant exposure, vaccination or immune globulin works best given early, so seek advice promptly rather than waiting for blood markers.
-
HBV triple panel: HBsAg, anti-HBs and total anti-HBc
CDC describes first HBsAg detection as early as 1-2 weeks and as late as 11-12 weeks after exposure; this is not a universal triple-panel rule-out window.
Obtain baseline status/immunity assessment when indicated; clinicians choose follow-up based on susceptibility, source status, vaccination and exposure.
Specimens: Blood
Sources 1, 2
Early negatives, after treatment, and screening limits
An early negative result. Recent exposure can need follow-up even with a negative baseline panel. CDC occupational-exposure guidance uses approximately 6-month follow-up for susceptible exposed personnel; this is a protocol example, not automatic advice for every sexual contact.
After treatment. Infection monitoring and checking vaccine response are different tasks. Recent vaccination or immune globulin can affect interpretation of particular markers.
Screening limits. Anti-HBs can reflect vaccination; HBsAg, anti-HBc and context distinguish infection, immunity and susceptibility. Do not use an antibody-only result as a whole-panel replacement.
Kissing and body sites. HBV testing is blood-based, not a throat swab after kissing. Ordinary kissing alone is not a typical HBV-exposure indication.
Sources for testing guidance (5)
- CDC Pink Book. Chapter 10: Hepatitis B. 2024. cdc.gov
- CDC. Clinical Testing and Diagnosis for Hepatitis B. 2025. cdc.gov
- CDC. Responding to HBV Exposures in Health Care Settings. 2024. cdc.gov
- CDC STI Treatment Guidelines. Table 7: nonoccupational hepatitis B postexposure prophylaxis. 2021. cdc.gov
- CDC. Hepatitis B Basics. 2025. cdc.gov
Treatment
Acute hepatitis B usually receives supportive care. Chronic infection needs liver assessment, monitoring and sometimes antiviral therapy such as tenofovir or entecavir. These medicines suppress HBV but do not reliably eradicate it. Treatment and follow-up are individualized; do not stop chronic antivirals without medical advice. [42]
Actions
1. Establish status. Ask about the triple blood panel: HBsAg, anti-HBs and total anti-HBc. Vaccination, past infection and current infection produce different patterns. A clinician interprets ambiguous or isolated results. [43]
2. After an exposure, ask early. Someone unvaccinated or not immune who had contact with a person with HBV may be offered vaccine and HBIG. These work best early: after a sexual exposure they are unlikely to help beyond 14 days, so it is worth asking promptly. [44]
3. Look after close contacts. Sexual and household contacts are usually offered testing, and vaccination if they are not immune. Use condoms until immunity is confirmed when advised, and avoid sharing injection equipment or items that may carry blood. There is no single lookback period for every diagnosis. [42][71]
SCIENCE & CONTEXT
Hepatitis B / the evidence
History
A hepatitis B surface antigen was identified in 1965, followed by visualization of the virus in 1970. The first US vaccine was licensed in 1981 and a recombinant vaccine in 1986. These advances made HBV a preventable cause of liver cancer, although established chronic infection remains a different treatment challenge. [45]
Impact
HBV infects liver cells. A new infection may cause tiredness, nausea, dark urine or yellowing of the skin, or no symptoms at all. Most adults with a healthy immune system clear it; a minority develop long-term infection, which is much more common after infection in infancy. Long-term HBV can, over years and sometimes without symptoms, scar the liver or lead to liver cancer, which is why monitoring and treatment matter. [42][45]
A positive anti-HBs result can reflect vaccine protection; it must not be counted as infection. HBsAg suggests current infection, while anti-HBc indicates natural exposure rather than vaccination. The combined pattern, timing and clinical history determine interpretation. [43]
Probability at a glance
| Test pattern / context | Meaning for decisions |
|---|---|
HBsAg positive | Current infection needs clinical assessment |
Anti-HBs only after vaccination | Consistent with vaccine-derived immunity |
Anti-HBc plus anti-HBs; HBsAg negative | Often past resolved natural infection |
All three markers negative | Usually susceptible; vaccination is relevant |
This status table replaces an unsupported partner-probability table. Vaccine-derived antibodies, prior natural infection and active HBV are different endpoints. [43]
For someone susceptible to HBV, verifying vaccination and addressing a recent exposure promptly are more actionable than a speculative per-act number.